發送短信 : Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

            ______   _    _      ___      _____   
  ____     /_   _// | || | ||   / _ \\   / ____|| 
 |    \\    -| ||-  | || | ||  | / \ || / //---`' 
 | [] ||    _| ||_  | \\_/ ||  | \_/ || \ \\___   
 |  __//   /_____//  \____//    \___//   \_____|| 
 |_|`-`    `-----`    `---`     `---`     `----`  
 `-`